Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

CPI and UK drug majors plan a continuous tableting center

by Rick Mullin
April 12, 2019 | A version of this story appeared in Volume 97, Issue 15

 

A formulation facility at CPI's site in Sedgefield, England.
Credit: CPI
Formulation labs at CPI's site in Sedgefield, England

CPI, a British process development services firm, is collaborating with GlaxoSmithKline and AstraZeneca to establish a continuous wet granulation facility for small-scale development of solid-dose drugs. The Prospect CP system will include raw material blending and feeding, twin screw wet granulation, tableting, and in-line process analytics. The project, anticipated to take 2 years to complete, is funded by an Innovate UK grant.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.